ONCOSEMA

We are a purpose-driven company.

Our mission is to fight back cancer by shedding light on cancer monitoring thanks to actionable blood tests, improving patient management. 

It all started with a conviction, the one that detecting Circulating Tumor Cells (CTC) with a blood draw is the cornerstone of cancer management.

CTC are targets full of information because there are the viable agents directly responsible for cancer progression and aggressiveness. In the meantime, detecting signs of cancer at the cellular scale allows a general approach, easily useable in routine and complementary of molecular analyses.

Moreover, CTC are easily accessible, thanks to a simple blood draw which is a minimally invasive and harmless intervention for patients. Finally, to be deeply impactful, we believe that a test must be widely used and thus affordable and adapted to labs workflow. Our tests are dedicated to Oncologists, to assist them to choose the best therapeutic options for their patients.

High levels of Circulating Tumor Cells are associated with :

• A high risk of metastasis
• Chemotherapy and immunotherapy resistance
• Higher recurrence and lower patient overall survival

What challenges does Oncosema tackle?

Even though the monitoring of CTC rates in blood is an efficient biomarker to give real-time insights into cancer development, CTC remain exceedingly rare events among all the peripheral blood cells. 

Oncosema patented technology can specifically capture and detect CTC in extremely complex environments.

Why is Oncosema technology innovative?

We own an exclusive license of a patent, describing an innovative method for the detection of CTC using specific antibodies targeting surface glycan markers, also known as TACA for Tumor Associated Carbohydrate Antigens.

Oncosema technology:

• SPECIFICITY

  Targets TACA that are exclusively present on CTC (and totally absent from regular blood cells).

• SENSITIVITY

  Efficiently detects all CTC subtypes, whether they are epithelial or involved in epithelial-mesenchymal transition.

• BROAD SPECTRUM

  Sorts CTC shed by tumor from any organ.

• PRESERVE VIABILITY

  Preserves CTC viability, allowing various analyses.

   

Oncosema is a product provider for Research in Oncology

Oncosema addresses Clinical Oncology Research Laboratories and CRO with solutions for CTC sorting :

Reagents (Immuno Magnetic Separation kits, anti-CTC antibodies (conjugated or not)

Manual and automated sorting devices.

Oncosema gives translational researchers tools to :

Selectively CAPTURE CTC from a blood sample, COUNT them, and CULTURE them.

ONCOSEMA CAN BE IMPLEMENTED AS A PRE-TREATMENT METHOD ON BLOOD SAMPLE TO UNLEACH THE PERFORMANCES OF A LARGE SPECTRUM OF DOWNSTREAM ANALYSIS TECHNOLOGIES (GENOME, TRANSCRIPTOME ANALYSIS, DNA METHYLATION PROFILES, STUDY OF METABOLIC PATHWAYS…).

Oncosema is a technology provider for the development of Clinical applications in Oncology

There are many challenges to face in dealing with the progression of cancer cases around the world. We deeply believe that CTC sorting will have an increasing role to play in this battle.

56% In the next 20 years, worldwide cancer cases are expected to increase from 19.3 millions to 30.2 millions.

Oncosema addresses Pharmaceutical and Diagnostic companies to develop operational tools for Oncologists based on liquid biopsy :

-Identification of second-lines therapy for patients with metastatic cancers

-Determination of prognosis : assessment of cancer aggressiveness

-Follow-up treatment efficiency in real-time

-Early detection of cancer recurrence